If approved, Zenas will enter the RMS market, which is currently dominated by anti-CD20 antibodies like Roche’s Ocrevus.

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that ...

Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...

Add Yahoo as a preferred source to see more of our stories on Google. A logo of Sanofi at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and other conditions.

A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera®. The drug is the most widely prescribed ...

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson's disease, researchers say. The oral drug, dimethylfumarate, or DMF, ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Sanofi SAN-0.38%decrease; red down pointing triangle said a U.S. regulatory decision on its tolebrutinib experimental treatment for a type of multiple sclerosis would be delayed again, and that a late ...